Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3–17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial

George F Gao ,Xiaohu Zuo,Fangjun Li ,Zhe Chen ,Peng He ,Danni Wang ,Siyuan Zhang ,Leilei Ci ,Lianpan Dai ,Shuo Yang ,Zhifang Ying ,Tao Huang ,Mengyu Ling ,Lihui Gong ,Guangyan Wang ,Huaiyu Yang ,Jiufeng Sun ,George F Gao ,Xilu Wang ,Zhongliang Hu ,Fan Ding ,Yan Li

doi:10.1016/s2352-4642(22)00376-5

Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3–17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial

George F Gao , Xiaohu Zuo + Show 20 more

Open Access

https://doi.org/10.1016/s2352-4642(22)00376-5

Copy DOI

Journal: The Lancet Child & Adolescent Health	Publication Date: Feb 17, 2023
Citations: 10

Affiliation: Hunan Provincial Center for Disease Control and Prevention, National Institutes for Food and Drug Control, Xiangtan University, Institute of Microbiology, Chinese Academy of Sciences, Guangdong Provincial Center for Disease Control and Prevention

#Geometric Mean Ratio #Seroconversion Rate + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3–17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial

Full Text